

Consolidated Financial Results for the Fiscal Year Ended March 31, 2026 (Under Japanese GAAP)

Company name: OSAKA SODA Co., Ltd.
 Listing: Tokyo Stock Exchange
 Securities code: 4046
 URL: <http://www.osaka-soda.co.jp>
 Representative: Kenshi Terada, Representative Director, President and Chief Executive Officer
 Inquiries: Toru Imamura, Executive Officer, General Manager, Administration Division
 Telephone: +81-6-6110-1560
 Scheduled date to of annual general meeting of shareholders: June 26, 2026
 Scheduled date to commence dividend payments: June 12, 2026
 Scheduled date to file annual securities report: June 25, 2026
 Preparation of supplementary material on financial results: Yes
 Holding of quarterly financial results briefing: Yes

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the fiscal year ended March 31, 2026(from April 1, 2025, to March 31, 2026)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

Fiscal year ended	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
March 31, 2026	99,961	3.7	17,634	33.1	19,608	38.5	15,460	49.6
March 31, 2025	96,434	2.0	13,246	26.2	14,154	17.9	10,332	35.0

Note: Comprehensive income For the fiscal year ended March 31, 2026: ¥20,453 million [106.5%]
 For the fiscal year ended March 31, 2025: ¥9,904 million [(25.5)%]

Fiscal year ended	Basic earnings per share	Diluted earnings per share	Return on equity	Ratio of ordinary profit to total assets	Ratio of operating profit to net sales
	Yen	Yen	%	%	%
March 31, 2026	123.96	—	12.7	12.2	17.6
March 31, 2025	81.54	—	9.2	9.3	13.7

Reference: Share of profit (loss) of entities accounted for using equity method

As of March 31, 2026: ¥23 million

As of March 31, 2025: ¥22 million

Note: The Company implemented a 5-for-1 stock split for common shares with an effective October 1, 2024.

Basic earnings per share is calculated based on the assumption that the stock split was implemented at the beginning of previous fiscal year.

(2) Consolidated financial position

As of	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
March 31, 2026	168,345	127,320	75.6	1,036.37
March 31, 2025	153,935	115,596	75.1	918.45

Reference: Equity

As of March 31, 2026: ¥127,320 million

As of March 31, 2025: ¥115,591 million

(3) Consolidated cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
As of	Millions of yen	Millions of yen	Millions of yen	Millions of yen
March 31, 2026	19,875	(5,364)	(9,273)	48,802
March 31, 2025	17,049	(8,135)	(4,221)	43,314

2. Cash dividends

	Annual dividends per share					Total cash dividends (Total)	Payout ratio (Consolidated)	Ratio of dividends to net assets (Consolidated)
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total			
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
Fiscal year ended March 31, 2025	—	45.00	—	10.00	—	2,400	23.3	2.1
Fiscal year ended March 31, 2026	—	12.00	—	16.00	28.00	3,469	22.5	2.9
Fiscal year ending March 31, 2027 (Forecast)	—	14.00	—	14.00	28.00		25.3	

Note: The Company implemented a 5-for-1 stock split for common shares with an effective October 1, 2024. Concerning the year-end dividend per share for the fiscal year ended March 31, 2025, the dividend amount based on the number of shares after the stock split is shown, and the total full-year dividend is displayed as “-”. Based on the number of shares prior to the stock split, the year-end dividend for the fiscal year ended March 31, 2025, is 50 yen for a full-year dividend of 95 yen per share.

3. Consolidated financial results forecasts for the fiscal year ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings Per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
First half year (cumulative)	52,000	6.5	8,800	8.5	9,500	6.6	6,400	(5.3)	52.10
Full year	106,000	6.0	19,000	7.7	20,400	4.0	13,600	(12.0)	110.70

*** Notes**

(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change in scope of consolidation): None

(2) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(iv) Restatement: None

(3) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of March 31, 2026	133,660,085 shares
As of March 31, 2025	133,660,085 shares

(ii) Number of treasury shares at the end of the period

As of March 31, 2026	10,808,065 shares
As of March 31, 2025	7,804,540 shares

(iii) Average number of shares outstanding during the period

Fiscal year ended March 31, 2026	124,727,034 shares
Fiscal year ended March 31, 2025	126,710,860 shares

Note: The Company implemented a stock split at a ratio of five shares for each share of common stock, effective October 1, 2024. The weighted average number of shares outstanding has been calculated assuming that the stock split had been effected at the beginning of the previous consolidated fiscal year.

[Reference] Overview of non-consolidated financial results

1. Non-consolidated financial results for the fiscal year ended March 31, 2026 (from April 1, 2025, to March 31, 2026)

(1) Non-consolidated operating results

(Percentages indicate year-on-year changes.)

Fiscal year ended	Net sales		Operating profit		Ordinary profit		Profit	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Mar 31,2026	76,047	7.0	14,986	38.3	16,727	43.0	13,619	55.4
Mar 31,2025	71,057	5.6	10,834	43.8	11,701	41.5	8,761	70.0

Fiscal year ended	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Mar 31,2026	109.19	—
Mar 31,2025	69.14	—

Note: The Company implemented a 5-for-1 stock split for common shares with an effective October 1, 2024.

Basic earnings per share is calculated based on the assumption that the stock split was implemented at the beginning of previous fiscal year.

(2) Non-consolidated financial position

As of	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
Mar 31,2026	140,084	103,062	73.6	838.91
Mar 31,2025	130,336	94,404	72.4	750.10

Reference: Equity

As of Mar 31,2026: ¥103,062 million

As of Mar 31,2025: ¥94,404 million

* Financial results reports are exempt from quarterly review conducted by certified public accountants or an audit corporation.

* Proper use of earnings forecasts, and other special matters

In this document, statements other than historical facts are forward looking statements that reflect the Company's plans and expectations. These forward-looking statements involve risks, uncertainties and other factors that may cause our actual results and achievements to differ from those anticipated in these statements. Please refer to "1. Overview of Operating Results (4) Future outlook of Forward-looking Statement, Including Consolidated financial results Forecasts" on page 4 of the attached documents.

(Attached Documents)

INDEX

1. Overview of Operating Results	
(1) Overview of Operating Results for the Fiscal Year	2
(2) Overview of Financial Position	3
(3) Overview of Cash Flows	4
(4) Future outlook of Forward-looking Statement, Including Consolidated financial results Forecasts	4
2. Basic Approach to the Selection of Accounting Standards	5
3. Consolidated Financial Statements and Notes to Consolidated Financial Statements	6
(1) Consolidated Balance Sheets	6
(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income	8
(3) Consolidated Statements of Changes in Net Assets	10
(4) Consolidated Statements of Cash Flows	12
(5) Notes to Consolidated Financial Statements	14
(Notes on Premise of Going Concern)	14
(Segment Information and Other Items)	14
(Per Share Information)	17
(Significant event after the reporting period)	17
4. Others	18
(1) Changes in Officers	18

1. Overview of Operating Results

(1) Overview of Operating Results for the Fiscal Year

During the consolidated fiscal year under review, the Japanese economy continued its gradual recovery, with an improvement in the employment and income situation and a pickup in consumer spending and capital investment. On the other hand, the risk of a downward swing in the economy is increasing due to factors such as the impact of the situation in the Middle East, the impact of U.S. tariffs, stagnation of the Chinese economy, and continuing price hikes, and the outlook remains uncertain.

In light of these circumstances, for this final year of our medium-term management plan, Shape the Future-2025 (FY2023 to FY2025), our group has been steadily implementing specific measures in line with the plan's three basic policies: continuous strengthening of our base in existing businesses, strengthening of new product creation capabilities, and promotion of sustainability management.

In terms of the "continuous strengthening of our base in existing businesses," we have been working to enhance our business base by generating stable cash flows and actively investing in growth areas. In the Basic chemicals business, in addition to efforts aimed at reducing costs, we have been working to improve profitability by aggressively expanding sales of Epichlorohydrin as overseas market conditions improve. We will continue to invest in upgrading facilities to improve production efficiency and reduce costs in order to strengthen business foundations so that we can generate stable earnings. In the Functional chemicals business, we were able to increase sales by promoting sales expansion activities to existing customers and promoting new business development, but sales for some products decreased as a result of reduced demand. For Allyl Ethers, we have increased the capacity of our shipping facilities this fiscal year and plan to increase production capacity by approximately 1.2 times the current level by March 2027, further solidifying our position as having one of the world's top market shares. In the Healthcare business, the demand for pharmaceutical purification materials for diabetes and obesity medications has continued to expand, and sales volume has been steadily increasing. Following the completion of new facilities at the Matsuyama Plant in September 2024 and the expansion of the Amagasaki Plant in September 2025, approximately one year ahead of schedule, production capacity has approximately doubled compared to FY2023, and a supply system is now in place that can meet the current increase in demand. Furthermore, in light of the rapid development of generic entry and biosimilars, we have decided to approximately double the current capacity at the Amagasaki and Matsuyama Plants by February 2028, at a total cost of over 10 billion yen. Through a series of capital investments, we will secure an even more stable supply system and strengthen our competitiveness.

In terms of the "strengthening of new product creation capabilities," the development of materials for next-generation storage batteries, such as ultra-high ionic conductive polymers for all-solid batteries, which were selected as a NEDO Green Innovation Fund project, is progressing smoothly. We decided to build a pilot facility during this fiscal year to establish a mass production system. Regarding the size exclusion and highly alkali-resistant columns launched last year, we are working to expand new adoption and sales are steadily increasing. For ADME gel for preparative use, we have started sample work for customers in working toward adoption. For lactic acid bacterium OS-1010, following its function of maintaining skin elasticity, we started human trials on maintaining cognitive function, etc., which has been progressing smoothly.

In terms of the "promotion of sustainability management," we have reviewed our policy on ESG disclosure initiatives and improved our ESG score. We are expanding opportunities for dialogue with institutional investors, and, taking into account the opinions obtained through such discussions, we are working to enhance shareholder returns by improving capital efficiency and introducing progressive dividends. Aiming to develop human resources by promoting operational reform activities as an investment in human capital, we are working to create a comfortable work environment and improve employee engagement. As part of this effort, we relocated our head office in August 2025 to revitalize communication and attract a diverse and talented workforce. In addition, we have decided to grant restricted stock to the Employee Shareholding Association in order to assist employees in building their assets, enhance awareness in management participation among Group employees, and promote greater sharing of value with shareholders.

Consequently, net sales for the current consolidated fiscal year increased 3.7% year on year to ¥99,961 million. In terms of profit, operating income increased 33.1% year on year to ¥17,634 million, ordinary income increased 38.5% year on year to ¥19,608 million, and profit attributable to owners of parent

increased 49.6% year on year to ¥15,460 million. Each stage of income for the consolidated fiscal year reached a record high.

<Basic Chemicals>

Net sales of Chlor-Alkali products increased due to an increase in sales volume resulting from the resolution of supply problems caused by the manufacturing equipment problems at the Mizushima Plant.

Net sales of Epichlorohydrin increased due to an increase in sales volume resulting from the resolution of supply problems and improved overseas market conditions.

As a result of the above, net sales in the Basic chemicals business increased 10.9% year on year to ¥41,741 million.

<Functional Chemicals>

In the Synthetic rubbers business, net sales of Acrylic Rubber increased due to increased production capacity resulting from the completion of last year's debottlenecking, but net sales of Epichlorohydrin Rubber decreased due to a decline in automobile production in regions such as Europe.

For synthetic resins, net sales of DAP resin increased due to strong sales in Europe, and net sales of DAP monomer increased due to replacing competing products in the U.S. and China.

Net sales of Allyl Ethers decreased due to the fact that, although there were signs of improvement, the Chinese market has not yet recovered to the previous year's level.

As a result of the above, net sales in the Functional chemicals business decreased 4.0% year on year to ¥27,935 million.

<Healthcare>

Net sales of pharmaceutical purification materials increased due to a steady growth in demand for diabetes and obesity medications.

Net sales of active pharmaceutical ingredients (APIs) and their intermediates increased, as although sales of products such as intermediates of medications for diabetes complications decreased, sales of intermediates of medications for the treatment of infectious diseases and intermediates for anticancer drugs increased.

As a result of the above, net sales in the Healthcare business increased 6.9% year on year to ¥14,563 million.

<Trading and Others>

Net sales decreased due to a decline in sales of inorganic chemicals and building materials.

As a result of the above, net sales in the Trading and others business decreased 2.3% year on year to ¥15,649 million.

(2) Overview of Financial Position

(Assets)

Current assets were ¥99,076 million, an increase of 6.6% compared to the end of the previous fiscal year. This was mainly due to an increase of ¥5,516 million in cash and deposits and ¥1,549 million in notes and accounts receivable – trade and contract assets.

Non-current assets were ¥69,269 million, an increase of 13.5% compared to the end of the previous fiscal year. This was mainly due to increases of ¥7,293 million in investment securities, ¥848 million in intangible assets, and ¥646 million in property, plant and equipment.

As a result, total assets at the end of the fiscal year were ¥168,345 million, an increase of 9.4% compared to the end of the previous fiscal year.

(Liabilities)

Current liabilities were ¥32,373 million, an increase of 3.1% compared to the end of the previous fiscal year. This was mainly due to increases of ¥1,578 million in notes and accounts payable—trade and ¥1,161 million in income taxes payable.

Non-current liabilities were ¥8,652 million, an increase of 24.4% compared to the end of the previous fiscal year. This was mainly due to an increase of ¥2,025 million in deferred tax liabilities.

As a result, total liabilities were ¥41,025 million, an increase of 7.0% compared to the end of the previous fiscal year.

(Net assets)

Net assets at the end of the fiscal year were ¥127,320 million, an increase of 10.1% compared to the end of the previous fiscal year. This was mainly due to an increase of ¥12,698 million in retained earnings and ¥5,035 million in valuation difference on available-for-sale securities.

(3) Overview of Cash Flows

Cash and cash equivalents at the end of the fiscal year under review amounted to ¥48,802 million, an increase of ¥5,488 million compared to the end of the previous fiscal year. The status of each type of cash flow during the fiscal year and the main contributing factors were as follows.

(Cash flow from operating activities)

Net cash provided by operating activities amounted to ¥19,875 million. This was mainly due to profit before income taxes amounting to ¥21,535 million.

(Cash flow from investing activities)

Net cash used in investing activities amounted to ¥5,364 million. This was mainly due to payments of ¥6,529 million for the acquisition of property, plant and equipment.

(Cash flow from financing activities)

Net cash used in financing activities amounted to ¥9,273 million. This was mainly due to payments of ¥6,005 million for the purchase of treasury shares and dividend payments of ¥2,731 million.

(4) Future outlook of Forward-looking Statement, Including Consolidated financial results Forecasts

With regard to the future economic outlook, while a gradual recovery of the economy is expected due to improvements in employment and income situations, the economic situation is expected to remain difficult due to concerns regarding the risk of an economic downturn as a result of the impact of the situation in the Middle East, U.S. tariffs, etc.

It is against this backdrop that we formulated our new medium-term management plan, “Transform Our Future 2030” (FY2026 to FY2030).

Our aim is to realize our “ideal image” for 2035, the 120th anniversary since our founding, with the plan’s three basic policies; “Rebuilding the Value of Existing Businesses and Accelerating Growth in Healthcare,” “Creating New Businesses by Mobilizing Companywide Capabilities,” and “Strengthening the Management Foundation to Adapt to Changes in the Business Environment”.

The company will work together as one to achieve an operating income of ¥30,000 million by FY2030.

In terms of “Rebuilding the Value of Existing Businesses and Accelerating Growth in Healthcare,” we will promote portfolio management by accelerating growth in the healthcare sector while strengthening the competitiveness of existing businesses.

In the Basic chemicals business, we will deepen our electrolysis and AC/EP chains, promote investments in strengthening the business and reducing costs for sustainable growth.

In the Functional chemicals business, we will aim to maximize profitability by expanding the market share of existing products and cost reductions, while also working to create the next Global Niche Top products.

In the Healthcare business, for pharmaceutical purification materials, we aim to maintain and expand our top global market share by strategically expanding our manufacturing capacity early in anticipation of market expansion, and will enter the polymer gel market to build a new business foundation in growth areas such as nucleic acid and peptide pharmaceuticals.

For APIs and their intermediates, we will expand our portfolio by increasing our manufacturing capacity and making a full-scale entry into the biopharmaceutical business.

In terms of “Creating New Businesses by Mobilizing Companywide Capabilities,” we will drive the creation of new products by leveraging our proprietary technologies, mainly in the areas of “electronic materials” and “life science materials,” while strategically utilizing the knowledge, networks, and other resources of corporate divisions throughout the company.

In the field of “electronic materials,” we are positioning high-ionic-conductivity materials for all-solid-state batteries as our next Global Niche Top product, aiming to commercialize them by 2030 through the establishment of mass production technology and grow them into a new pillar of earnings by 2035.

In the field of “life science materials,” for biopharmaceuticals, we will strengthen our contract development and manufacturing business for VHH antibodies, and promote the development and commercialization of materials that contribute to improving QoL, such as those related to pharmaceuticals and aging care.

In terms of “Strengthening the Management Foundation to Adapt to Changes in the Business Environment,” we will work on our “human resource strategy,” “DX promotion,” “safe and stable production,” “risk management,” and “carbon neutrality” in order to build an organization that balances efficiency and adaptability, and advance sustainability management.

For our “human resource strategy,” we will improve managerial skills, raise the level of organizational capabilities, and build a human resource management foundation with the aim of becoming a company where employees can fully demonstrate their abilities.

For “DX promotion,” we will promote innovation and transformation in production technology and R&D, as well as improve operational efficiency on a company-wide scale, through the use of AI and data.

For “safe and stable production,” we will prevent accidents and problems by promoting the establishment of a maintenance management system and strengthening voluntary maintenance activities.

For “risk management,” we will further strengthen our risk management system in light of the diversification of major company-wide risks associated with the expansion of the company’s size.

For “carbon neutrality,” we will promote efforts such as improving energy efficiency, promoting the use of bio-derived raw materials, and introducing non-fossil fuel electric power in order to achieve carbon neutrality by FY2050.

For the next fiscal year, we project net sales of ¥106,000 million, operating profit of ¥19,000 million, ordinary profit of ¥20,400 million, and profit attributable to owners of parent of ¥13,600 million. Regarding the situation in the Middle East, we assume a limited impact based on the situation during the first three months for the fiscal year ending March 31,2027. We aim to minimize these impacts by implementing timely price revisions for our products in response to rising raw material costs.

2. Basic Approach to the Selection of Accounting Standards

Osaka Soda Group prepares the consolidated financial statements in accordance with Japanese generally accepted accounting principles, taking into accounts the comparability between periods and companies. In adopting International Financial Reporting Standards, Osaka Soda Group intends to take appropriate measures, examining internal and external situation.

3. Consolidated Financial Statements

(1) Consolidated Balance Sheets

(Millions of yen)

	As of March 31, 2025	As of March 31, 2026
Assets		
Current assets		
Cash and deposits	16,339	21,855
Notes and accounts receivable - trade, and contract assets	25,742	27,291
Electronically recorded monetary claims - operating	4,576	3,470
Securities	26,974	26,946
Merchandise and finished goods	9,817	10,994
Work in process	2,280	1,746
Raw materials and supplies	5,707	5,088
Other	1,496	1,690
Allowance for doubtful accounts	(19)	(7)
Total current assets	92,916	99,076
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	9,490	9,430
Machinery, equipment and vehicles, net	14,675	14,118
Land	2,246	2,242
Leased assets, net	531	480
Construction in progress	1,979	3,136
Other, net	371	533
Total property, plant and equipment	29,295	29,941
Intangible assets		
Goodwill	118	73
Software	82	2,266
Other	1,320	30
Total intangible assets	1,521	2,370
Investments and other assets		
Investment securities	28,510	35,803
Long-term loans receivable	9	6
Deferred tax assets	715	223
Other	1,544	1,500
Allowance for doubtful accounts	(578)	(577)
Total investments and other assets	30,201	36,956
Total non-current assets	61,018	69,269
Total assets	153,935	168,345

(Millions of yen)

	As of March 31, 2025	As of March 31, 2026
Liabilities		
Current liabilities		
Notes and accounts payable - trade	13,117	14,695
Short-term borrowings	7,172	7,172
Income taxes payable	2,947	4,108
Provision for bonuses	953	972
Current portion of long-term borrowings	76	—
Other	7,119	5,424
Total current liabilities	31,385	32,373
Non-current liabilities		
Long-term borrowings	387	—
Lease liabilities	675	554
Deferred tax liabilities	3,973	5,999
Retirement benefit liability	1,207	653
Asset retirement obligations	557	658
Other	150	785
Total non-current liabilities	6,953	8,652
Total liabilities	38,339	41,025
Net assets		
Shareholders' equity		
Share capital	15,871	15,871
Capital surplus	17,020	17,026
Retained earnings	76,151	88,849
Treasury shares	(6,410)	(12,405)
Total shareholders' equity	102,633	109,342
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	11,316	16,351
Deferred gains or losses on hedges	(56)	79
Foreign currency translation adjustment	1,026	669
Remeasurements of defined benefit plans	671	877
Total accumulated other comprehensive income	12,957	17,978
Non-controlling interests	4	—
Total net assets	115,596	127,320
Total liabilities and net assets	153,935	168,345

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income

1) Consolidated Statements of Income

(Millions of yen)

	Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026
Net sales	96,434	99,961
Cost of sales	67,487	66,232
Gross profit	28,946	33,728
Selling, general and administrative expenses	15,700	16,094
Operating profit	13,246	17,634
Non-operating income		
Interest income	78	173
Dividend income	784	1,103
Share of profit of entities accounted for using equity method	22	23
Foreign exchange gains	—	433
Subsidy income	292	319
Other	176	144
Total non-operating income	1,353	2,198
Non-operating expenses		
Interest expenses	128	142
Loss on tax purpose reduction entry of non-current assets	35	51
Foreign exchange losses	110	—
Compensation expenses	49	—
Other	121	30
Total non-operating expenses	444	224
Ordinary profit	14,154	19,608
Extraordinary income		
Gain on sale of businesses	—	313
Gain on sale of non-current assets	684	1
Gain on sale of investment securities	139	1,523
Gain on liquidation of subsidiaries and associates	18	460
Total extraordinary income	843	2,298
Extraordinary losses		
Loss on retirement of non-current assets	163	307
Loss on sale of non-current assets	—	2
Head office relocation expenses	—	62
Impairment losses	187	—
Total extraordinary losses	351	371
Profit before income taxes	14,646	21,535
Income taxes - current	4,537	6,121
Income taxes - deferred	(217)	(22)
Total income taxes	4,319	6,099
Profit	10,326	15,435
Loss attributable to non-controlling interests	(5)	(25)
Profit attributable to owners of parent	10,332	15,460

2) Consolidated statements of Comprehensive Income

(Millions of yen)

	Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026
Profit	10,326	15,435
Other comprehensive income		
Valuation difference on available-for-sale securities	(840)	5,035
Deferred gains or losses on hedges	(128)	136
Foreign currency translation adjustment	139	(350)
Remeasurements of defined benefit plans, net of tax	387	206
Share of other comprehensive income of entities accounted for using equity method	19	(9)
Total other comprehensive income	(422)	5,018
Comprehensive income	9,904	20,453
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	9,906	20,481
Comprehensive income attributable to non-controlling interests	(2)	(27)

(3) Consolidated Statements of Changes in Net Assets

FY2024(Fiscal year ended March 31, 2025)

(Millions of yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at beginning of period	15,871	17,014	68,102	(4,611)	96,377
Changes during period					
Dividends of surplus			(2,283)		(2,283)
Profit attributable to owners of parent			10,332		10,332
Purchase of treasury shares				(1,801)	(1,801)
Disposal of treasury shares		6		3	10
Net changes in items other than shareholders' equity					
Total changes during period	—	6	8,048	(1,798)	6,256
Balance at end of period	15,871	17,020	76,151	(6,410)	102,633

	Accumulated other comprehensive income					Non-controlling interests	Total net assets
	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income		
Balance at beginning of period	12,156	71	871	283	13,383	4	109,765
Changes during period							
Dividends of surplus							(2,283)
Profit attributable to owners of parent							10,332
Purchase of treasury shares							(1,801)
Disposal of treasury shares							10
Net changes in items other than shareholders' equity	(840)	(128)	155	387	(425)	(0)	(425)
Total changes during period	(840)	(128)	155	387	(425)	(0)	5,830
Balance at end of period	11,316	(56)	1,026	671	12,957	4	115,596

FY2025(Fiscal year ended March 31, 2026)

(Millions of yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at beginning of period	15,871	17,020	76,151	(6,410)	102,633
Changes during period					
Dividends of surplus			(2,762)		(2,762)
Profit attributable to owners of parent			15,460		15,460
Purchase of treasury shares				(6,000)	(6,000)
Disposal of treasury shares		5		5	10
Net changes in items other than shareholders' equity					
Total changes during period	—	5	12,698	(5,995)	6,708
Balance at end of period	15,871	17,026	88,849	(12,405)	109,342

	Accumulated other comprehensive income					Non-controlling interests	Total net assets
	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income		
Balance at beginning of period	11,316	(56)	1,026	671	12,957	4	115,596
Changes during period							
Dividends of surplus							(2,762)
Profit attributable to owners of parent							15,460
Purchase of treasury shares							(6,000)
Disposal of treasury shares							10
Net changes in items other than shareholders' equity	5,035	136	(357)	206	5,020	(4)	5,015
Total changes during period	5,035	136	(357)	206	5,020	(4)	11,724
Balance at end of period	16,351	79	669	877	17,978	—	127,320

(4) Consolidated Statements of Cash Flows

(Millions of yen)

	Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026
Cash flows from operating activities		
Profit before income taxes	14,646	21,535
Depreciation	3,920	4,337
Amortization of goodwill	44	44
Increase (decrease) in allowance for doubtful accounts	572	(13)
Increase (decrease) in provision for bonuses	26	18
Increase (decrease) in retirement benefit liability	(792)	(553)
Interest and dividend income	(862)	(1,277)
Interest expenses	128	142
Foreign exchange losses (gains)	28	(152)
Loss on retirement of non-current assets	163	307
Loss (gain) on sale of non-current assets	(684)	1
Loss on tax purpose reduction entry of non-current assets	35	51
Impairment losses	187	—
Loss (gain) on sale of short-term and long-term investment securities	(139)	(1,523)
Loss (gain) on sale of businesses	—	(313)
Decrease (increase) in accounts receivable - trade, and contract assets	4,657	(318)
Decrease (increase) in inventories	159	5
Increase (decrease) in trade payables	(2,206)	1,449
Subsidy income	(292)	(319)
Increase (decrease) in accrued consumption taxes	157	17
Share of loss (profit) of entities accounted for using equity method	(22)	(23)
Loss (gain) on liquidation of subsidiaries and associates	(18)	(460)
Other, net	(626)	536
Subtotal	19,084	23,490
Interest and dividends received	875	1,292
Interest paid	(128)	(142)
Proceeds from insurance income	8	5
Subsidies received	97	202
Income taxes paid	(2,886)	(4,972)
Net cash provided by (used in) operating activities	17,049	19,875

(Millions of yen)

	Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026
Cash flows from investing activities		
Purchase of property, plant and equipment	(6,737)	(6,529)
Proceeds from sale of property, plant and equipment	763	7
Proceeds from redemption of securities	500	—
Purchase of intangible assets	(824)	(8,60)
Purchase of investment securities	(1,886)	(570)
Proceeds from sale of investment securities	244	2,237
Proceeds from sale of shares of subsidiaries and associates	—	—
Proceeds from sale of businesses	—	423
Subsidies received	194	116
Other, net	(389)	(187)
Net cash provided by (used in) investing activities	(8,135)	(5,364)
Cash flows from financing activities		
Repayments of long-term borrowings	(49)	(434)
Purchase of treasury shares	(1,802)	(6,005)
Dividends paid	(2,255)	(2,731)
Other, net	(113)	(102)
Net cash provided by (used in) financing activities	(4,221)	(9,273)
Effect of exchange rate change on cash and cash equivalents	189	250
Net increase (decrease) in cash and cash equivalents	4,881	5,488
Cash and cash equivalents at beginning of period	38,432	43,314
Cash and cash equivalents at end of period	43,314	48,802

(5) Notes to Consolidated Financial Statements

(Notes on Premise of Going Concern)

Not applicable

(Segment Information and Other Items)

1. Overview of Reportable segment

Reportable segments of the Osaka Soda group are those for which separate financial information is available and the Board of Directors review regularly to make management resource allocation decisions and evaluate performance. Based on the versatility of manufacturing and service and the similarity of markets, the Osaka Soda group divides its business into four business segments, including "Basic chemicals," "functional Chemicals," "Healthcare," and "Trading and Others,"

"Basic Chemicals," manufactures and sells (i)chlor-alkali products, (ii)epichlorohydrin and (iii) allyl chloride, etc.

"Functional chemicals," manufactures and sells (i)allyl ethers, (ii)epichlorohydrin rubber, (iii) DAP resin, (iv)modifiers for energy-saving tires and (v) electrodes, etc.

"Healthcare," manufactures and sells (i)pharmaceutical purification materials, and (ii)active pharmaceutical ingredients and intermediates, etc.

"Trading and Others," includes (i)sales and transportation and storage of chemical products, (ii)sales and manufacturing of consumer products, (iii) sales and manufacturing of building materials and (iv)materials recycling, etc.

2. Calculation method for Net sales, Income, Assets and Other items of each reportable segment

The method of accounting for reported business segments is the same as described in "Basis of preparation of consolidated financial statements,". Intersegment sales or reclassifications are based on current market prices. Reportable segment income is based on operating income.

3. Information concerning Net sales, Income, Assets and Other items of each reporting segment

The previous fiscal year ended March 31, 2025 (from April 1, 2024, to March 31, 2025)

(Millions of yen)

	Basic chemicals	Functional chemicals	Healthcare	Trading and Others	Total	Adjustments *1	Consolidated *2
Net sales							
Japan	34,425	8,302	3,759	13,762	60,249	—	60,249
China	—	8,116	1,847	1,597	11,561	—	11,561
Asia	2,119	5,354	2,799	509	10,782	—	10,782
Europe	392	3,900	4,205	133	8,631	—	8,631
Others	698	3,423	1,072	13	5,207	—	5,207
Revenue from Contracts with Customers	37,636	29,097	13,684	16,015	96,434	—	96,434
Other Revenue	—	—	—	—	—	—	—
External sales	37,636	29,097	13,684	16,015	96,434	—	96,434
Intersegment sales or reclassifications	4	729	—	3,408	4,142	(4,142)	—
Total	37,641	29,826	13,684	19,424	100,576	(4,142)	96,434
Segment income	2,275	4,327	7,031	904	14,538	(1,292)	13,246
Segment assets	41,013	20,018	22,309	17,683	101,024	52,910	153,935
Other items							
Depreciation	1,776	866	866	32	3,543	377	3,920
Impairment losses	—	172	—	—	172	15	187
Amortization of goodwill	—	—	44	—	44	—	44
Investment to entities accounted for using equity method	—	362	—	—	362	—	362
Increase of current and noncurrent assets	1,886	965	3,338	115	6,305	57	6,362

Notes1: Adjustments are as follows.

- (1) Adjustments of segment income of ¥(1,292) million are corporate expenses not allocated to reportable segments. Most of above-mentioned corporate expenses are not attributable to a reporting segment and related to fundamental research and development.
- (2) Adjustments of segment assets of ¥52,910 million are corporate assets of ¥52,910 million, which are not allocated to reportable segments. Above-mentioned corporate assets are mainly parent company's assets, which are surplus operating funds (cash and short-term securities), long term investment capital (investment securities, etc.), and related to administrative, research and development departments.
- (3) Adjustments of Increase of current and noncurrent assets of ¥57 million are for administrative department and research and development department investment.

Notes2: Segment income is adjusted to operating income of consolidated statement of income.

The fiscal year ended March 31, 2026 (from April 1, 2025, to March 31, 2026)

(Millions of yen)

	Basic chemicals	Functional chemicals	Healthcare	Trading and Others	Total	Adjustments *1	Consolidated *2
Net sales							
Japan	34,681	8,355	4,018	13,598	60,653	—	60,653
China	—	9,858	2,546	1,388	13,793	—	13,793
Asia	4,891	4,966	2,629	418	12,905	—	12,905
Europe	941	2,635	4,274	216	8,068	—	8,068
Others	1,227	2,119	1,165	28	4,540	—	4,540
Revenue from Contracts with Customers	41,741	27,935	14,635	15,649	99,961	—	99,961
Other Revenue	—	—	—	—	—	—	—
External sales	41,741	27,935	14,635	15,649	99,961	—	99,961
Intersegment sales or reclassifications	5	699	—	3,005	3,710	(3,710)	—
Total	41,746	28,635	14,635	18,655	103,672	(3,710)	99,961
Segment income	6,194	4,634	7,156	946	18,931	(1,297)	17,634
Segment assets	44,468	22,231	25,458	16,749	108,907	59,438	168,345
Other items							
Depreciation	1,929	748	1,220	28	3,926	411	4,337
Impairment losses	—	—	—	—	—	—	—
Amortization of goodwill	—	—	44	—	44	—	44
Investment to entities accounted for using equity method	—	361	—	—	361	—	361
Increase of current and noncurrent assets	3,690	850	1,165	54	5,762	117	5,879

Notes1: Adjustments are as follows.

- (1) Adjustments of segment income of ¥(1,297) million are corporate expenses not allocated to reportable segments. Most of above-mentioned corporate expenses are not attributable to a reporting segment and related to fundamental research and development.
- (2) Adjustments of segment assets of ¥59,438 million are corporate assets of ¥59,208 million, which are not allocated to reportable segments. Above-mentioned corporate assets are mainly parent company's assets, which are surplus operating funds (cash and short-term securities), long term investment capital (investment securities, etc.), and related to administrative, research and development departments.
- (3) Adjustments of Increase of current and noncurrent assets of ¥117million are for administrative department and research and development department investment.

Notes2: Segment income is adjusted to operating income of consolidated statement of income.

(Per Share Information)

	Fiscal year ended	
	March 31, 2025	March 31, 2026
Net assets per share (Yen)	918.45	1,036.37
Earnings per share (Yen)	81.54	123.96

Note1: Diluted earnings per share is not shown as there are no diluted shares.

Note2: Basis for calculation of earnings per share and diluted earnings per share is as follows.

	Fiscal year ended	
	March 31, 2025	March 31, 2026
Earnings per share		
Net income (Millions of yen)	10,332	15,460
Amount not attributable to owners of common stock (Millions of yen)	—	—
Net income related to owner of common stock (Millions of yen)	10,332	15,460
Weighted average number of common stock (Thousands of shares)	126,710	124,727

Note3: Basis for calculation of Net assets is as follows.

	Fiscal year ended	
	March 31, 2025	March 31, 2026
Amount of Net assets (Millions of yen)	115,596	127,320
Amount deducted from Net assets (Millions of yen)	4	—
Net assets related to owner of common stock (Millions of yen)	115,591	127,320
Number of common stocks for calculation of Net assets per share (Thousands of shares)	125,855	122,852

(Significant event after the reporting period)

Not applicable

4. Others

(1) Changes in Officers

① Change of Representative Directors

None

② Changes of Other Officers (Effective for June 26, 2026)

1. New Audit & Supervisory Board Member Candidate

Yusaku Akasaki Outside Audit & Supervisory Board Member

2. Audit & Supervisory Board Members to Retire

Shinji Mori Outside Audit & Supervisory Board Member